A carregar...
Acquired resistance is oncogene and drug agnostic
Recent approvals of TRK inhibitors have demonstrated the success of a tumor agnostic approach to oncogene-targeted therapy across cancers. Collective data from acquired resistance studies suggest that these mechanisms, which include both kinase domain mutations and bypass signaling via RTK-RAS-RAF-M...
Na minha lista:
| Publicado no: | Cancer Cell |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7437928/ https://ncbi.nlm.nih.gov/pubmed/31614114 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2019.09.011 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|